EUVIMEDEUVIMED entdecken
Crossref

2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial

JAMY ARD, MICHAEL KNIGHT, ANDERS B. BOJESEN, DOMENICA RUBINO, SIGNE STENSEN, ANDREA TRAINA, LAUREN WILSON, ROBERT KUSHNER

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2846-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JAMY ARD und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: It is important to understand if the effect of semaglutide 2.4mg (sema) on major adverse cardiovascular events (MACE) varies by race/ethnicity given prevalent disparities. This SELECT trial post hoc analysis assessed the efficacy and safety of sema for MACE risk reduction in patients with overweight/obesity and CVD without diabetes stratified by race/ethnicity.

Methods

Participants randomized to receive sema or placebo were grouped by self-reported race/ethnicity to assess the treatment effect on MACE. Cox regression models testing for interactions (race/ethnicity x treatment effect) were performed; adverse events (AEs) leading to discontinuation were summarized descriptively.

Results

Race/ethnicity were balanced across treatment arms (Figure). Sema-treated patients exhibited similar reductions in weight from baseline (Asian, Other, White, Hispanic, not Hispanic: -9%; Black: -10%). Sema consistently reduced the risk of MACE across race/ethnicity. Asian patients receiving sema had slightly greater MACE risk reduction vs those receiving placebo. The proportions of sema-treated patients with AEs (Asian: 11%; Hispanic: 15%; Black: 16%; Other, White, not Hispanic: 17%) and serious AEs (Asian, Hispanic: 3%; White, not Hispanic, Other: 4%; Black: 5%) leading to discontinuation were similar across races/ethnicities.

Conclusion

Sema reduced the relative risk of MACE and had a consistent safety profile regardless of patient race or ethnicity. Disclosure J. Ard: Consultant; Current; Novo Nordisk, Eli Lilly and Company, Amgen Inc., Roche Pharmaceuticals, Viking Therapeutics, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Zealand Pharma A/S. Research Support; Current; Weight Watchers. Consultant; Current; Epitomee. M. Knight: Consultant; Current; Novo Nordisk, Boehringer Ingelheim International GmbH. Consultant; Ended; Currax Pharmaceuticals. A.B. Bojesen: Employee; Current; Novo Nordisk. D. Rubino: Other - Advisory panel, research support, shareholder; Current; AbbVie Inc. Other - steering committee, research support; Current; Amgen Inc. Other - advisory panel, steering committee, research support; Current; AstraZeneca. Other - advisory panel, research support; Current; Boehringer Ingelheim International GmbH. Other - advisory panel, speaker, research support,; Current; Novo Nordisk. Consultant; Current; Lilly, Shionogi & Co., Ltd. Advisory Panel; Current; Neurocrine Biosciences, Inc., Regeneron Pharmaceuticals Inc. Consultant; Current; Pfizer Inc., Roche Pharmaceuticals, Cytoki. Other - advisory, research support; Current; Terns Pharmaceutical. Advisory Panel; Current; Neuraly Inc. Consultant; Current; Ferring Pharmaceuticals. Consultant; Ended; NodThera. S. Stensen: Employee; Current; Novo Nordisk A/S. A. Traina: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Novo Nordisk. L. Wilson: Employee; Current; Novo Nordisk. R. Kushner: Advisory Panel; Current; AbbVie Inc. Consultant; Ended; Altimmune. Advisory Panel; Current; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk A/S. Consultant; Current; Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Viking Therapeutics. Advisory Panel; Current; Antag, Weight Watchers, Structure.

Zitieren

APA

ARD, J., KNIGHT, M., BOJESEN, A. B., RUBINO, D., STENSEN, S., TRAINA, A., WILSON, L., & KUSHNER, R. (2026). 2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2846-lb

Vancouver

ARD J, KNIGHT M, BOJESEN AB, RUBINO D, STENSEN S, TRAINA A, et al. 2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2846-lb

BibTeX
@article{ARD2026,
  author = {ARD, JAMY and KNIGHT, MICHAEL and BOJESEN, ANDERS B. and RUBINO, DOMENICA and STENSEN, SIGNE and TRAINA, ANDREA and WILSON, LAUREN and KUSHNER, ROBERT},
  title = {2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2846-lb}
}
Kostenlos starten →